CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

CVRx, Inc. (NASDAQ:CVRX) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $14.00.

A number of analysts have recently weighed in on CVRX shares. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of CVRx in a report on Tuesday, August 5th. William Blair upgraded shares of CVRx to a “strong-buy” rating in a report on Monday, July 7th.

CVRx Stock Down 4.5%

Shares of CVRx stock opened at $7.87 on Friday. The company has a debt-to-equity ratio of 0.85, a current ratio of 11.99 and a quick ratio of 10.78. CVRx has a 1 year low of $4.30 and a 1 year high of $18.55. The firm’s 50-day moving average is $7.64 and its two-hundred day moving average is $8.00. The stock has a market cap of $205.80 million, a price-to-earnings ratio of -3.75 and a beta of 1.26.

CVRx (NASDAQ:CVRX) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. The firm had revenue of $13.59 million during the quarter, compared to the consensus estimate of $13.22 million. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts expect that CVRx will post -1.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CVRx

Several hedge funds and other institutional investors have recently modified their holdings of CVRX. Larson Financial Group LLC purchased a new position in shares of CVRx in the 1st quarter valued at approximately $28,000. Mount Lucas Management LP purchased a new position in shares of CVRx in the 2nd quarter valued at approximately $30,000. GAMMA Investing LLC raised its position in shares of CVRx by 1,469.3% in the 1st quarter. GAMMA Investing LLC now owns 4,598 shares of the company’s stock valued at $56,000 after purchasing an additional 4,305 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of CVRx in the 2nd quarter valued at approximately $59,000. Finally, Whittier Trust Co. purchased a new position in shares of CVRx in the 1st quarter valued at approximately $73,000. 75.27% of the stock is owned by hedge funds and other institutional investors.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.